Sleep Aging and Risk for Alzheimer's 2.0

Alzheimer Disease Clinical Trial

— SARA  

Official title:

Sleep Aging and Risk for Alzheimer's Resubmission 2.0

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03278119
• Other study ID #: 17-01005
• Secondary ID: R01AG056031
• Status: Recruiting
• Start date: May 1, 2018
• Est. completion date: May 30, 2025

Study information

• Verified date: August 2023
• Source: NYU Langone Health
• Contact: Gabriela Silva Albornoz
• Phone: 2122635053
• Email: Gabriela.SilvaAlbornoz[@]nyulangone.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Age-related sleep changes and common sleep disorders like obstructive sleep apnea (OSA) may increase amyloid burden and represent risk factors for cognitive decline in the elderly. We will directly interrogate the brain using a 2-night nocturnal polysomnography (NPSG) and amyloid deposition using C-PiB PET/MR both at baseline and at the 24-month follow-up. This study has the potential to identify the mechanisms by which age-related sleep changes contribute to AD neurodegeneration in cognitively normal elderly, the group that could profit the most from sleep preventive strategies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 170
• Est. completion date: May 30, 2025
• Est. primary completion date: May 30, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 55 Years to 75 Years

Eligibility

Inclusion Criteria:

To be eligible to participate in this study, an individual must meet all of the following

criteria:

• Male and female subjects with normal cognition and 55-75 years.
• Within normal limits on neurological and psychiatric examinations. All subjects enrolled will have a CDR=0.
• All subjects will have had a minimum of 12 years of education. Among minority subjects >80% of the elderly individuals coming to the NYU-ADC meet this criterion. The education restriction reduces performance variance on cognitive test measures and improves the sensitivity for detecting pathology and disease progression using the robust norms available at NYU. Given most subjects will meet this criterion we do not consider this a major selection bias or generalization limitation for this study.
• An informed family member or life-partner (preferably bed-partner) will be interviewed to confirm the reliability of the subject interview. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation

in this study:

• History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, mental retardation or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders).
• Significant history of alcoholism or drug abuse.
• History of psychiatric illness (e.g., schizophrenia, bipolar, PTSD, or life-long history of major depression).
• Geriatric Depression Scale (short form)>6.
• Insulin dependent diabetes.
• Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological conditions.
• Physical impairment of such severity as to adversely affect the validity of psychological testing.
• Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging.
• Medications affecting cognition: Narcotic analgesics, chronic use of medications with anticholinergic activity, anti-Parkinsonian medications (carbidopa/levodopa, amantadine, bromocriptine, selegiline). Others: amphetamines, amphetamine-like compounds, appetite suppressants, phenothiazines, reserpine, buspirone, clonidine, disulfiram, guanethidine, MAO inhibitors, theophylline, tricyclic antidepressants, salicylates, cholinesterase inhibitors and memantine.
• History of a first-degree family member with early onset (age <60 years) dementia.
• Irregular sleep-wake rhythms (based on the actigraphy recordings) or severe OSA (AHI4%=30).
• Chronic use of antidepressants and melatonin are allowed.
• Excessive daytimes sleepiness (Epworth Sleepiness Scale >10) or history of CVE (arrhythmias, heart valve disease, cardiomyopathy, carotid or coronary artery disease and chest pain) will not be allowed in the OSA groups.

Related Conditions & MeSH terms

• Alzheimer Disease
• Sleep Apnea

Intervention

Diagnostic Test:
• PET Scan and nocturnal polysomnography
Amyloid PET scans will be used to assess amyloid burden in the brain, and nocturnal polysomnography will be used to assess sleep and cardiopulmonary variables

Locations

Country	Name	City	State
United States	Healthy Brain Aging and Sleep Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
NYU Langone Health	National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Establishing how mild-to-moderate OSA increases AD risk will inform novel preventive therapies for AD.		2.5 years
Secondary	Establishing that SWS quality is associated with longitudinal amyloid deposition will identify a key mechanism by which age increases AD risk.		2.5 years